Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators

Ichiro Yasue, Shinji Matsunaga, Taro Kishi, Kiyoshi Fujita, Nakao Iwata

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: There is uncertainty about the efficacy and tolerability of serotonin 2A (5-HT2A) receptor negative modulators for Parkinson's disease psychosis (PDP). Objective: This is the first meta-analysis of randomized placebo-controlled trials (RCTs) testing negative modulators of the 5-HT2A receptor as a treatment for PDP. Methods: The primary outcome was the Scale for Assessment of Positive Symptoms (SAPS)-hallucinations (H) and -delusions (D) scores (SAPS-H+D). Other outcome measures were SAPS-H, SAPS-D, the Unified Parkinson's Disease Rating Scale Part II and III (UPDRS-II+III), discontinuation rates, and individual adverse events. Results: Four RCTs were identified that met inclusion criteria, all assessing the 5-HT2A inverse agonist pimavanserin (including 417 drug-treated and 263 placebo-treated PDP patients). Pimavanserin significantly decreased SAPS-H+D scores compared to placebo [weighted mean differences (WMD) = -2.26, 95% confidence interval (95%CI) = -3.86 to -0.67, p = 0.005, I2 = 30%, N= 4 studies, n = 502 patients]. Moreover, pimavanserin was superior to placebo for reducing SAPS-H (WMD= -2.15, 95%CI = -3.45 to -0.86, p = 0.001, I2 = 0%, N=2, n = 237) and SAPS-D scores (WMD= -1.32, 95%CI = -2.32 to -0.32, p = 0.010, I2 = 0%, N=2, n = 237). Pimavanserin was associated with less orthostatic hypotension than placebo (risk ratio = 0.33, 95%CI = 0.15-0.75, p = 0.008, I2 = 0%, number needed to harm = 17, p = 0.01, N=3, n = 476). There were no significant differences in rates of all-cause discontinuation, adverse events, and death, UPDRS-II+III scores, and incidences of individual adverse events (other than orthostatic hypotension) between pimavanserin and placebo groups. Conclusions: Pooled RCT results suggest that pimavanserin is beneficial for the treatment of PDP and is well tolerated.We did not identify other negative modulators of the 5-HT2A receptor for the treatment of PDP.

Original languageEnglish
Pages (from-to)733-740
Number of pages8
JournalJournal of Alzheimer's Disease
Volume50
Issue number3
DOIs
Publication statusPublished - 02-02-2016

Fingerprint

Receptor, Serotonin, 5-HT2A
Symptom Assessment
Psychotic Disorders
Parkinson Disease
Meta-Analysis
Placebos
Confidence Intervals
Orthostatic Hypotension
Randomized Controlled Trials
Therapeutics
Serotonin 5-HT2 Receptor Agonists
Delusions
Hallucinations
Uncertainty
Pimavanserin
Odds Ratio
Outcome Assessment (Health Care)
Incidence

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{f1cee40d8fa9433690142a82a1cd49c1,
title = "Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators",
abstract = "Background: There is uncertainty about the efficacy and tolerability of serotonin 2A (5-HT2A) receptor negative modulators for Parkinson's disease psychosis (PDP). Objective: This is the first meta-analysis of randomized placebo-controlled trials (RCTs) testing negative modulators of the 5-HT2A receptor as a treatment for PDP. Methods: The primary outcome was the Scale for Assessment of Positive Symptoms (SAPS)-hallucinations (H) and -delusions (D) scores (SAPS-H+D). Other outcome measures were SAPS-H, SAPS-D, the Unified Parkinson's Disease Rating Scale Part II and III (UPDRS-II+III), discontinuation rates, and individual adverse events. Results: Four RCTs were identified that met inclusion criteria, all assessing the 5-HT2A inverse agonist pimavanserin (including 417 drug-treated and 263 placebo-treated PDP patients). Pimavanserin significantly decreased SAPS-H+D scores compared to placebo [weighted mean differences (WMD) = -2.26, 95{\%} confidence interval (95{\%}CI) = -3.86 to -0.67, p = 0.005, I2 = 30{\%}, N= 4 studies, n = 502 patients]. Moreover, pimavanserin was superior to placebo for reducing SAPS-H (WMD= -2.15, 95{\%}CI = -3.45 to -0.86, p = 0.001, I2 = 0{\%}, N=2, n = 237) and SAPS-D scores (WMD= -1.32, 95{\%}CI = -2.32 to -0.32, p = 0.010, I2 = 0{\%}, N=2, n = 237). Pimavanserin was associated with less orthostatic hypotension than placebo (risk ratio = 0.33, 95{\%}CI = 0.15-0.75, p = 0.008, I2 = 0{\%}, number needed to harm = 17, p = 0.01, N=3, n = 476). There were no significant differences in rates of all-cause discontinuation, adverse events, and death, UPDRS-II+III scores, and incidences of individual adverse events (other than orthostatic hypotension) between pimavanserin and placebo groups. Conclusions: Pooled RCT results suggest that pimavanserin is beneficial for the treatment of PDP and is well tolerated.We did not identify other negative modulators of the 5-HT2A receptor for the treatment of PDP.",
author = "Ichiro Yasue and Shinji Matsunaga and Taro Kishi and Kiyoshi Fujita and Nakao Iwata",
year = "2016",
month = "2",
day = "2",
doi = "10.3233/JAD-150818",
language = "English",
volume = "50",
pages = "733--740",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis : A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators. / Yasue, Ichiro; Matsunaga, Shinji; Kishi, Taro; Fujita, Kiyoshi; Iwata, Nakao.

In: Journal of Alzheimer's Disease, Vol. 50, No. 3, 02.02.2016, p. 733-740.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis

T2 - A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators

AU - Yasue, Ichiro

AU - Matsunaga, Shinji

AU - Kishi, Taro

AU - Fujita, Kiyoshi

AU - Iwata, Nakao

PY - 2016/2/2

Y1 - 2016/2/2

N2 - Background: There is uncertainty about the efficacy and tolerability of serotonin 2A (5-HT2A) receptor negative modulators for Parkinson's disease psychosis (PDP). Objective: This is the first meta-analysis of randomized placebo-controlled trials (RCTs) testing negative modulators of the 5-HT2A receptor as a treatment for PDP. Methods: The primary outcome was the Scale for Assessment of Positive Symptoms (SAPS)-hallucinations (H) and -delusions (D) scores (SAPS-H+D). Other outcome measures were SAPS-H, SAPS-D, the Unified Parkinson's Disease Rating Scale Part II and III (UPDRS-II+III), discontinuation rates, and individual adverse events. Results: Four RCTs were identified that met inclusion criteria, all assessing the 5-HT2A inverse agonist pimavanserin (including 417 drug-treated and 263 placebo-treated PDP patients). Pimavanserin significantly decreased SAPS-H+D scores compared to placebo [weighted mean differences (WMD) = -2.26, 95% confidence interval (95%CI) = -3.86 to -0.67, p = 0.005, I2 = 30%, N= 4 studies, n = 502 patients]. Moreover, pimavanserin was superior to placebo for reducing SAPS-H (WMD= -2.15, 95%CI = -3.45 to -0.86, p = 0.001, I2 = 0%, N=2, n = 237) and SAPS-D scores (WMD= -1.32, 95%CI = -2.32 to -0.32, p = 0.010, I2 = 0%, N=2, n = 237). Pimavanserin was associated with less orthostatic hypotension than placebo (risk ratio = 0.33, 95%CI = 0.15-0.75, p = 0.008, I2 = 0%, number needed to harm = 17, p = 0.01, N=3, n = 476). There were no significant differences in rates of all-cause discontinuation, adverse events, and death, UPDRS-II+III scores, and incidences of individual adverse events (other than orthostatic hypotension) between pimavanserin and placebo groups. Conclusions: Pooled RCT results suggest that pimavanserin is beneficial for the treatment of PDP and is well tolerated.We did not identify other negative modulators of the 5-HT2A receptor for the treatment of PDP.

AB - Background: There is uncertainty about the efficacy and tolerability of serotonin 2A (5-HT2A) receptor negative modulators for Parkinson's disease psychosis (PDP). Objective: This is the first meta-analysis of randomized placebo-controlled trials (RCTs) testing negative modulators of the 5-HT2A receptor as a treatment for PDP. Methods: The primary outcome was the Scale for Assessment of Positive Symptoms (SAPS)-hallucinations (H) and -delusions (D) scores (SAPS-H+D). Other outcome measures were SAPS-H, SAPS-D, the Unified Parkinson's Disease Rating Scale Part II and III (UPDRS-II+III), discontinuation rates, and individual adverse events. Results: Four RCTs were identified that met inclusion criteria, all assessing the 5-HT2A inverse agonist pimavanserin (including 417 drug-treated and 263 placebo-treated PDP patients). Pimavanserin significantly decreased SAPS-H+D scores compared to placebo [weighted mean differences (WMD) = -2.26, 95% confidence interval (95%CI) = -3.86 to -0.67, p = 0.005, I2 = 30%, N= 4 studies, n = 502 patients]. Moreover, pimavanserin was superior to placebo for reducing SAPS-H (WMD= -2.15, 95%CI = -3.45 to -0.86, p = 0.001, I2 = 0%, N=2, n = 237) and SAPS-D scores (WMD= -1.32, 95%CI = -2.32 to -0.32, p = 0.010, I2 = 0%, N=2, n = 237). Pimavanserin was associated with less orthostatic hypotension than placebo (risk ratio = 0.33, 95%CI = 0.15-0.75, p = 0.008, I2 = 0%, number needed to harm = 17, p = 0.01, N=3, n = 476). There were no significant differences in rates of all-cause discontinuation, adverse events, and death, UPDRS-II+III scores, and incidences of individual adverse events (other than orthostatic hypotension) between pimavanserin and placebo groups. Conclusions: Pooled RCT results suggest that pimavanserin is beneficial for the treatment of PDP and is well tolerated.We did not identify other negative modulators of the 5-HT2A receptor for the treatment of PDP.

UR - http://www.scopus.com/inward/record.url?scp=84957927887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957927887&partnerID=8YFLogxK

U2 - 10.3233/JAD-150818

DO - 10.3233/JAD-150818

M3 - Article

C2 - 26757194

AN - SCOPUS:84957927887

VL - 50

SP - 733

EP - 740

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -